Platinib is a targeted drug that treats what

Platinib is a targeted therapy drug with broad application prospects. It is mainly used to treat malignant tumors such as non-small cell lung cancer (NSCLC) and thyroid cancer. It works by inhibiting tumor cell proliferation and angiogenesis, particularly in cancer patients who carry RET gene mutations.

The main mechanism of action of Platinib is that it can interfere with the abnormal signaling of RET receptors. RETThe receptor is a tyrosine kinase that plays an important role in the development of the central nervous system, peripheral nervous system and kidneys under normal circumstances. However, when the RET gene is abnormal, it can be the cause of a variety of solid tumors. Platinib effectively prevents the growth and spread of cancer cells by precisely inhibiting the activity of the RET receptor.

It is worth noting that Platinib does not targetBCR-ABL. BCR-ABL is an abnormal tyrosine kinase that is mainly associated with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Platinib's main target is RET, which makes it excellent in treating certain types of cancer, such as non-small cell lung cancer and thyroid cancer.

Platinib, as a new type of targeted therapy, has shown good efficacy in multiple clinical trials. For example, for patients with RET fusion-positive non-small cell lung cancer who have undergone platinum-containing chemotherapy, platinib has achieved a high overall response rate and is well tolerated and safe. In addition, platinib has also been shown to have significant therapeutic effects on other types of cancer, such as thyroid cancer.

In general, platinib provides a new treatment option for cancer patients carrying RET gene mutations, and is expected to help them achieve better quality of life and longer survival.

xa0

Reference link:https://en.wikipedia.org/wiki/Ponatinib